These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16313350)

  • 41. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects.
    Santen R; Cavalieri E; Rogan E; Russo J; Guttenplan J; Ingle J; Yue W
    Ann N Y Acad Sci; 2009 Feb; 1155():132-40. PubMed ID: 19250200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.
    Nakamura T; Imai Y; Matsumoto T; Sato S; Takeuchi K; Igarashi K; Harada Y; Azuma Y; Krust A; Yamamoto Y; Nishina H; Takeda S; Takayanagi H; Metzger D; Kanno J; Takaoka K; Martin TJ; Chambon P; Kato S
    Cell; 2007 Sep; 130(5):811-23. PubMed ID: 17803905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Understanding the oestrogen action in experimental and clinical atherosclerosis.
    Arnal JF; Douin-Echinard V; Brouchet L; Tremollières F; Laurell H; Lenfant F; Gadeau AP; Guery JC; Gourdy P
    Fundam Clin Pharmacol; 2006 Dec; 20(6):539-48. PubMed ID: 17109647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rheumatic diseases: the effects of inflammation on bone.
    Walsh NC; Crotti TN; Goldring SR; Gravallese EM
    Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogens and SERMs in coronary heart disease.
    Regitz-Zagrosek V; Wintermantel TM; Schubert C
    Curr Opin Pharmacol; 2007 Apr; 7(2):130-9. PubMed ID: 17317318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The expression of estrogen receptors and the effects of estrogen on human periodontal ligament cells.
    Cao M; Shu L; Li J; Su J; Zhang W; Wang Q; Guo T; Ding Y
    Methods Find Exp Clin Pharmacol; 2007 Jun; 29(5):329-35. PubMed ID: 17805434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estrogen receptor beta in health and disease.
    Imamov O; Shim GJ; Warner M; Gustafsson JA
    Biol Reprod; 2005 Nov; 73(5):866-71. PubMed ID: 16033996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms.
    Babiker FA; Lips DJ; Delvaux E; Zandberg P; Janssen BJ; Prinzen F; van Eys G; Grohé C; Doevendans PA
    Acta Physiol (Oxf); 2007 Jan; 189(1):23-31. PubMed ID: 17280554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs.
    Tapia-Gonzalez S; Carrero P; Pernia O; Garcia-Segura LM; Diz-Chaves Y
    J Endocrinol; 2008 Jul; 198(1):219-30. PubMed ID: 18460549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T cells and post menopausal osteoporosis in murine models.
    Pacifici R
    Arthritis Res Ther; 2007; 9(2):102. PubMed ID: 17349065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis.
    Stubelius A; Andréasson E; Karlsson A; Ohlsson C; Tivesten A; Islander U; Carlsten H
    Clin Immunol; 2011 Jul; 140(1):37-46. PubMed ID: 21459677
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of estrogen receptor subtypes for vascular maintenance.
    Luksha L; Kublickiene K
    Gynecol Endocrinol; 2009 Feb; 25(2):82-95. PubMed ID: 19253103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines.
    Chrzan BG; Bradford PG
    Mol Nutr Food Res; 2007 Feb; 51(2):171-7. PubMed ID: 17266178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isoflavones made simple - genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits.
    McCarty MF
    Med Hypotheses; 2006; 66(6):1093-114. PubMed ID: 16513288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential expression of estrogen receptors in women with systemic lupus erythematosus.
    Rider V; Li X; Peterson G; Dawson J; Kimler BF; Abdou NI
    J Rheumatol; 2006 Jun; 33(6):1093-101. PubMed ID: 16755656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Signaling by estrogens.
    Cheskis BJ; Greger JG; Nagpal S; Freedman LP
    J Cell Physiol; 2007 Dec; 213(3):610-7. PubMed ID: 17886255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases.
    Cutolo M; Brizzolara R; Atzeni F; Capellino S; Straub RH; Puttini PC
    Ann N Y Acad Sci; 2010 Apr; 1193():36-42. PubMed ID: 20398006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic lupus erythematosus and hormone replacement therapy.
    Gompel A; Piette JC
    Menopause Int; 2007 Jun; 13(2):65-70. PubMed ID: 17540136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.